You can also read more about cookies and similar technologies here. Otherwise, you agree to the use of the cookies as they are currently set.
Meridian’s antibodies are highly sensitive for the detection of SARS-CoV-2 and they are ideal for developing reliable and sensitive rapid antigen assays for the detection of active COVID-19 infections. Meridian has a novel antibody pair to trimeric SARS-CoV-2 S1 protein that is capable of recognizing the spike 1 (S1) protein in saliva samples regardless of its confirmation state (e.g. “up” or “down”). The antibodies bind to a linear epitope on the S1 protein that is distinct from the RBD protein which has epitopes that are conformation-dependent. Recent studies have shown that linear epitopes on the S1 protein are able elicit neutralizing antibodies in COVID-19 patients and have potent antigenicity, making them prime targets for diagnostic, therapeutic and vaccine targets. Li, Y., Lai, D., Zhang, H. et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol (2020).
Antibodies work as a pair and can detect SARS-CoV-2 trimeric spike protein down to ~300 pg/mL by using TMB substrate in ELISA assay. They bind to a linear epitope and are not conformation dependent. They are suitable for ELISA, Lateral Flow and Western Blot applications and they can be used as a positive control antibody in neutralizing assays with Meridian’s SARS-CoV-2 Spike mutant recombinant antigens.
Antibodies work as a pair and are suitable for use in ELISA, Lateral Flow and Western Blot. They do not cross react with any other coronavirus except SARS-CoV.